medigraphic.com
ISSN 1028-4818 (Electronic)

2014, Number 4

<< Back Next >>

Mul Med 2014; 18 (4)

Metabolic syndrome in adults over 40 years in 2 medical offices.

Sánchez CT, Cruz ME, Sanfiel VL, Milanés OMR, Valdés ILE

Language: Spanish
References: 27
Page: 1-16
PDF size: 381.31 Kb.


ABSTRACT

Introduction: the metabolic syndrome (SM), initially described by Reaven in 1988, is an association of metabolic disorders like dislipidemia, obesity, hypertension and the intolerance to the glucose.
Method: it was performed a transversal descriptive study in which there were included 239 patients.
Objective: to determine the presence of the metabolic syndrome in the patients belonging to 2 Family Medical Offices from the University Polyclinic Jimmy Hirtzel in Bayamo, during the period between January of 2009 until November of 2011.
Results: it was established the diagnostic of metabolic Syndrome according to the criteria of the Third Report National Cholesterol Education Program. From the amount of the sample it was diagnosed the metabolic syndrome in 38 patients, being significant the association between the age and the number of components of the metabolic syndrome, unlike the sex. Nevertheless, the greatest number of patients with metabolic syndrome belonged to the feminine sex. The parameters mostly associated with the diagnostic were the blood pressure, the hypertriglyceridemia and the abdominal obesity.
Conclusions: it was not found a significant influence in the alimentary habits and the levels of physical activity about the emergence of the metabolic syndrome


REFERENCES

  1. Pedrozo W, Castillo Rascón M, Bonneau G, Ibáñez de Pianesi M, Castro Olivera C, Jiménez de Aragón S. Síndrome metabólico y factores de riesgo asociados con el estilo de vida de adolescentes de una ciudad de Argentina, 2005. Rev Panam Salud Pública 2008; 24(3):149–60.

  2. Fernández-Bergés D, Consuegra-Sánchez L, Peñafiel J, Cabrera de León A, Vila J, Félix-Redondo FJ, Segura-Fragoso A, Lapetra J, Guembe MJ, Vega T, Fitó M, Elosua R, Díaz O, Marrugat J. Perfil metabólico-inflamatorio en la transición obesidad, síndrome metabólico y diabetes mellitus en población mediterránea. Estudio DARIOS Inflamatorio. Rev Esp Cardiol 2014; 67(8):624–631.

  3. Valdés E, Bencosme N. Síndrome metabólico y enfermedad cardiovascular en personas con diabetes mellitus tipo 2. Rev Cubana Endocrinol 2013; 24(2): 125-135.

  4. Zimmet P, Alberti G, Shaw JE. Mainstreaming the metabolic syndrome: a definitive definition. Med J Aust 2005; 183: 175-6.

  5. Srinivasan SR, Myers L, Berenson GS. Predictability of childhood adiposity and insulina for developing insulin resistance syndrome (syndrome X) in young adulthood: the Bogalusa Heart Study. Diabetes 2002; 51(1):204–9.

  6. Williams CL, Hayman LL, Daniels SR, Robinson TN, Steinberger J, Paridon S. Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in Young. American Heart Association. Circulation. 2002; 106(1): 143–60.

  7. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes, and cardiovascular risk in children. An American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young VERSION ON-LINE: ISSN 1028-4818 Multimed. Revista Médica. Granma RPNS 14 Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity and Metabolism). Circulation. 2003; 107(10): 1448–53.

  8. Bustillo SE, Pérez FY, Brito GA, González IA, Castañeda MD, Santos González M, Bustillo ME. Síndrome metabólico, un problema de salud no diagnosticado. Rev Cubana de Endocrinol 2011; 22(3): 167-181.

  9. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome, a new world wide definition. Lancet 2005; 366: 1059-1062.

  10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.

  11. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem. 1969; 6: 24.

  12. Buccolo G. Quantitative determination of serum triglycerides by use of enzimes. Clin Chem 1973; 19(5): 476-482.

  13. Lópes-Virella M, Stone MF, Ellis S. Cholesterol determinations in HDL separated by three different methods. Clin Chem 1977; 23:882-5.

  14. Kim JS, Lee HC, Choi BK, Lee HW, Park JS, Lee YH. Impact of metabolic syndrome on instent restenosis and clinical outcomes after percutaneous coronary stent implantation. Diabetes Research and Clinical Practice 2010; 88: 38-41.

  15. Mozaffarian D, Kamineni A, Prineas RJ, Siscovick DS. Metabolic syndrome and mortality in older adults: The Cardiovascular Health Study. Arch Intern Med 2008; 168(9): 969-78. VERSION ON-LINE: ISSN 1028-4818 Multimed. Revista Médica. Granma RPNS 15

  16. Alegría E, Castellano JM, Alegría A. Obesidad, Síndrome Metabólico y Diabetes: implicaciones cardiovasculares y actuación terapéutica. Rev Esp Cardiol 2008; 61(7): 752-64.

  17. Calderín Bouza, RO. Síndrome Metabólico VS Síndrome de Insulinorresistencia. Diferentes términos, Clasificaciones y enfoques: ¿Existe o no? Rev Cubana Endocrinol 2006; 17(3): 1-9.

  18. D Álvarez-Dongo1 J, Sánchez-Abanto G, Gómez-Guizado C. Tarqui-Mamani. Sobrepeso y obesidad: prevalencia y determinantes sociales del exceso de peso en la población peruana (2009-2010). Rev Peru Med Exp Salud Publica 2012; 29(3): 303-313.

  19. Nathan DM. Impaired Fasting Glucose and Impaired Glucose Tolerance. Diab Care 2007; 30(3): 753-9.

  20. Bloomgarden ZT. Third Annual World Congress on the Insulin Resistance Syndrome: mediators, antecedents and measurement. Diabetes Care 2006; 29(7):1700-6.

  21. Álvarez Gómez J. El Síndrome Metabólico y la actividad física como pilar importante en su tratamiento. Rev Cubana Cardiol Cir Cardiov 2010; 16(1): 51-63.

  22. Wiebe JC, Wägner AM, Novoa Mogollón FJ. Genética de la diabetes mellitus. Nefrologia Sup Ext 2011; 2(1):111-9.

  23. Bernal JA. Frechtel G. Análisis molecular de la disfunción de la célula β pancreática en la progresión de la diabetes tipo 2. Su aplicación a nuevos Bancos Terapéuticos. [Internet] 2008 [consultado 22 d enero del 2014]. Disponible en: http://www.google.com.cu/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CBwQFjAA&url=http%3A%2F%2Fwww.diabetes.org.ar%2Fdocs%2Fmonografia_bernal_jose.pdf&ei=A8VgVO6dFYSYgwT3t4GYDA&usg=AFQjCNEPbwNdcOgdInCvdZj1TTacrsWtow&bvm=bv.79189006,d.eXY&cad=rja VERSION ON-LINE: ISSN 1028-4818 Multimed. Revista Médica. Granma RPNS 16

  24. Lam TK, Carpentier A, Lewis GF. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab 2003; 284: E863-73.

  25. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004; 89: 2601-7.

  26. Montserrat L, Moreno-Franco B, Andrés-Esteban EM, Ledesma M, Laclaustra M, Alcalde V, Peñalvo JL, Ordová JM, Casasnovas JA. Sedentarismo y su relación con el perfil de riesgo cardiovascular, la resistencia a la insulina y la inflamación. Rev Esp Cardiol 2014; 67(6): 449–455.

  27. Pencina JM, D’Agostino BR, Massaro M. Predicting the 30-Year Risk of Cardiovascular Disease The Framingham Heart Study. Circulation 2009; 119: 3078-3084. Recibido: 8 de Julio del 2




2020     |     www.medigraphic.com